To a certain extent, the formerly embarrassing and intractable pattern of cancer therapy has been changed through the use of ICIs, hence Ipilimumab (Yervoy), the first anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody (mAb) and Pembrolizumab (Keytruda), the first mAb against programmed death-1 (PD-1) garnered their first global approvals for cancer treatment by United States Food and Drug Administration (FDA) in 2011 and 2014, respectively (4, 5). This evidence concerns the gene CTLA4 and cancer.